Prostate cancer treatment has a range no other common cancer has. At one end are men who are told, correctly, that the safest plan is to watch and do nothing. At the other are men receiving a radioactive medicine that travels through the blood and attaches to prostate cancer cells wherever they hide. Which end you are on depends on a handful of numbers from your PSA test, your biopsy, and your scans. This guide walks through what those numbers mean, what is approved at each stage, and what changed in the last 18 months.
Looking for Prostate Cancer Treatment Options?
Browse open clinical trials near you! We'll handle the follow-up.
The numbers that decide your options
PSA. A protein made by the prostate, measured in blood. It rises with cancer but also with benign enlargement and infection, which is why PSA alone never makes a diagnosis. How fast it rises, and whether it rises again after treatment, matters as much as the number.
Gleason score or grade group. From the biopsy: how abnormal the cells look, scored 6 to 10 or as grade group 1 to 5. Grade group 1 (Gleason 6) is low risk and often watched. Grade group 4 and 5 are high risk.
Stage and disease state. Localized (inside the prostate), locally advanced (through the capsule), or metastatic (spread to nodes, bones, or organs). Metastatic disease is further split into hormone sensitive, meaning hormone therapy still controls it, and castration resistant, meaning it is growing despite hormone therapy. Almost every treatment decision and every clinical trial starts with which of these you have. Our prostate cancer page walks through the stages in detail.
Localized prostate cancer: watching, surgery, or radiation
Active surveillance. For low risk cancer, and increasingly for some intermediate risk cancer, guidelines recommend monitoring with PSA tests, MRI, and repeat biopsies rather than treating. This is not doing nothing. It is avoiding the side effects of treatment, mainly urinary and sexual, for cancers that may never cause harm, while catching the minority that change. Roughly 6 in 10 American men with low risk prostate cancer now choose surveillance, up from about 1 in 10 fifteen years ago, one of the biggest shifts in cancer care of the past decade.
Surgery. Removing the prostate, usually with robotic assistance. Cures most localized cancer. Side effects on urinary control and erections are common at first and improve for most men over the following year.
Radiation. External beam radiation over several weeks, or brachytherapy, radioactive seeds placed inside the prostate. Radiation courses have shortened dramatically: what took eight or nine weeks a decade ago is now often delivered in five sessions, with the same results in trials. Higher risk localized disease usually adds hormone therapy for months to years.
Focal therapy. Treating only the tumor with heat, cold, ultrasound, or light activated drugs, sparing the rest of the prostate. Promising for side effects, still being tested for how well it controls cancer long term.
Advanced and metastatic prostate cancer
Hormone therapy. Prostate cancer feeds on testosterone. Lowering it with injections or pills (androgen deprivation therapy) has been the foundation of advanced disease treatment since the 1940s. It works for years but not forever.
Androgen receptor blockers. Newer pills such as enzalutamide, apalutamide, and darolutamide block the cancer's ability to use even tiny amounts of testosterone. They moved from castration resistant disease into hormone sensitive disease over the past decade; in June 2025 darolutamide (Nubeqa) was approved for metastatic hormone sensitive disease without chemotherapy, based on the ARANOTE trial in 669 men, in which the median time before the cancer progressed on scans was not yet reached, versus 25 months on placebo, a 46 percent reduction in that risk.
Chemotherapy. Docetaxel remains standard for men with high volume metastatic disease and for castration resistant disease, and is often combined with hormone drugs.
PARP inhibitors. Olaparib and similar pills for men whose cancer carries BRCA or related mutations, about 1 in 8 with metastatic disease. This is why genetic testing of the tumor is now standard once cancer has spread.
Targeted radiation: the biggest change in a decade. Lutetium 177 PSMA (Pluvicto) is a radioactive medicine given by infusion. It attaches to PSMA, a protein on most prostate cancer cells, and delivers radiation directly to them, wherever they are. Approved in 2022 for men who had exhausted other options, it was expanded in March 2025 to use before chemotherapy, after a trial showed it cut the risk of progression by 59 percent compared with switching hormone drugs. Then on July 31, 2026, the FDA approved it in combination with a hormone pathway drug for PSMA positive metastatic hormone sensitive disease, the earliest setting yet, with eligibility confirmed by a PSMA PET scan. In that trial it reduced the risk of progression or death by about a third when added to standard treatment.
What researchers are studying now
Making targeted radiation work for more men. Pluvicto only works when the cancer expresses enough PSMA. A trial of vorinostat with lutetium PSMA tests whether a second drug can raise PSMA levels in men whose cancer has too little of it, expanding who can benefit.
The BRCA question. For men with BRCA mutated metastatic disease, a trial comparing carboplatin chemotherapy with the PARP inhibitor olaparib asks which of two approaches that exploit the same weakness works better.
New drugs for resistant disease. ZEN003694 combined with enzalutamide tests a new mechanism against castration resistant disease, and a trial of inavolisib, a drug approved for breast cancer, tests it in metastatic castration resistant prostate cancer.
Treating the cancer, not the whole prostate. A photodynamic therapy trial for localized prostate cancer uses a light activated drug to destroy the tumor while sparing surrounding tissue, one of several focal approaches aiming to reduce the side effects that drive men away from treatment.
Finding it, and finding the right men. A study comparing a new biopsy needle system with the standard one, and a PSMA PET-MRI imaging study for detecting prostate cancer, both aim to make diagnosis more accurate, so that men with aggressive cancer are found and men with harmless cancer are not overtreated. A study measuring tumor DNA in blood tests whether it can guide treatment choices in castration resistant disease.
Protecting the heart. Hormone therapy raises cardiovascular risk, and heart disease is a leading cause of death in men with prostate cancer. A study using heart CT scans to manage cardiovascular risk in men on hormone therapy addresses a problem that grows as men live longer with the disease.
Why prostate cancer research takes time
The slow disease problem. Most prostate cancer grows slowly, so trials in localized disease need a decade or more to show whether a treatment prevents deaths. That is why so much evidence for early stage decisions, including active surveillance, took so long to mature.
The two speeds problem. The same disease that can be safely watched in one man kills another within a few years. Telling them apart is a research problem in itself, and genomic tests and imaging that try to do so are still being validated.
The screening pendulum. After a 2012 recommendation against routine PSA screening, testing fell, and advanced stage diagnoses began rising a few years later. The recommendation was softened in 2018, but the effects are still working through the numbers. Studies of smarter screening, using MRI and risk based approaches, aim to catch aggressive cancers without the overdiagnosis that prompted the original warning.
The representation problem. Black men are 67 percent more likely to be diagnosed and twice as likely to die of prostate cancer, yet make up a small fraction of trial participants. Several current studies name enrollment of Black men as an explicit goal. Here's why diversity in clinical trials matters so much.
Common myths about prostate cancer
"A high PSA means cancer."
Often it does not. Benign enlargement, infection, and even recent ejaculation or a bike ride raise PSA. A high reading means more testing, not a diagnosis.
"Every prostate cancer needs to be treated right away."
No. For low risk disease, active surveillance is a guideline recommended option, not a gamble. Treating cancers that would never cause harm exposes men to side effects for no benefit.
"Treatment always ends your sex life."
Side effects are real and common, but they vary widely by treatment, improve over time for many men, and are the subject of active research into nerve sparing surgery and focal therapy.
The stages, and what care usually looks like
Localized low risk disease is usually watched. Localized intermediate and high risk disease is treated with surgery or radiation, often with hormone therapy for higher risk. Locally advanced disease usually means radiation plus longer hormone therapy. Metastatic hormone sensitive disease is treated with hormone therapy plus an androgen receptor blocker, sometimes chemotherapy, and now for eligible men targeted radiation. Castration resistant disease brings the widest range: switching hormone drugs, chemotherapy, PARP inhibitors for mutation carriers, and lutetium PSMA. This is a description of usual practice, not a recommendation, and your plan belongs to you and your oncologist.
For trials, the disease state is the headline in nearly every title, along with markers like PSMA positive or BRCA mutated. Your disease state, PSA history, and grade group let you filter studies in minutes.
How to find a prostate cancer clinical trial
AllClinicalTrials.com lists prostate cancer studies recruiting across the US, from screening and focal therapy to Phase 3 trials for advanced disease. Two examples recruiting right now: the vorinostat with lutetium PSMA study for men with PSMA low metastatic castration resistant prostate cancer, and the photodynamic therapy trial for men with localized prostate cancer.
The application takes about 5 minutes: you answer questions about your disease state, PSA, biopsy grade, and treatments so far, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Three things to have ready: your current disease state and PSA, your Gleason score or grade group, and the list of treatments you have had.
Common questions
What is the newest treatment for prostate cancer? Lutetium 177 PSMA (Pluvicto), a targeted radioactive medicine,received its earliest approval yet on July 31, 2026, for PSMA positive metastatic hormone sensitive disease in combination with a hormone pathway drug, after being expanded to use before chemotherapy in March 2025. Darolutamide (Nubeqa) was approved for hormone sensitive metastatic disease in June 2025.
How many radiation treatments are needed for prostate cancer? It depends on the technique. Conventional external beam radiation is about 40 sessions over 8 weeks; moderately shortened courses are about 20 sessions over 4 weeks; and stereotactic radiation, now widely used for localized disease, is typically 5 sessions over one to two weeks. Brachytherapy is often a single procedure. Trials showed the shorter courses give equivalent results for most men.
Is prostate cancer deadly? It can be, but most men diagnosed with it do not die from it. It is the second leading cause of cancer death in men, with about 36,300 deaths expected in 2026, yet more than 3.5 million American men are living after a diagnosis. Cancer caught while localized has a five year survival near 100 percent; cancer found after distant spread has about 38 percent.
Do prostate cancer trials use placebo? Sometimes, but never in place of treatment. In advanced disease trials, a placebo is typically added to standard hormone therapy, and the comparison group receives full standard care. Many trials compare a new drug directly against an approved one instead. Our guide to placebo controlled trials explains how this works.
See clinical trials for prostate cancer recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Prostate Cancer Clinical Trials